世界の末期腎臓病市場2021-2028:治療別(移植、透析)、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)

◆英語タイトル:End Stage Renal Disease Market Size, Share & Trends Analysis Report By Treatment (Transplant, Dialysis), By Region (North America, Europe, APAC, LATAM, MEA), And Segment Forecasts, 2021 - 2028
◆商品コード:GV21FB002
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2021年1月25日
◆ページ数:171
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥678,300見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥792,300見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,020,300見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

グランドビューリサーチ社は、世界の末期腎臓病市場規模が2028年までに1,938憶ドルに達すると予測しています。2021年から2028年までに年平均12.7%成長する見通しです。本調査レポートでは、末期腎臓病の世界市場について調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、治療別(移植、透析)分析、地域別分析、競争状況などを掲載しています。
・調査手法・範囲
・エグゼクティブサマリー
・市場変動・動向・範囲
・末期腎臓病の世界市場規模:治療別(移植、透析)
・末期腎臓病の世界市場規模:地域別
・競争分析
【レポートの概要】

End Stage Renal Disease Market Growth & Trends

The global end stage renal disease market size is anticipated to reach USD 193.8 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 12.7% from 2021 to 2028. The increasing number of patients suffering from end stage renal disease (also known as kidney failure) and the rising prevalence of hypertension and diabetes are fueling the market growth.

Chronic kidney disease (CKD) is one of the major causes of increasing kidney failure rates among patients. According to the CDC, it is estimated that more than 37 million people in the U.S. suffer from CKD, whereas globally more than 500 million people (12-18% of the world population) are affected.

The COVID-19 pandemic has impacted the healthcare industry and people suffering from end stage renal disease (ESRD) are at a higher risk of contracting this virus as they have to visit the hospitals often for dialysis. Center-based hemodialysis is the main renal replacement medium in most countries, with almost 90% of the ESRD population opting for it. Hemodialysis patients have to stay in hospitals for 4 hours minimum, 3 times a week, and come in frequent contact with the medical staff and other patients. All these factors increase their risk of infection.

Technological advancements including the innovation of wearable artificial kidney (WAK) in the treatment of renal failure are expediting the overall market growth. WAK is a portable dialysis device designed to enable patients to live healthier as it controls blood pressure, improves clearance of wastes from the blood, and allows ESRD or CKD patients for a less strict diet, resulting in lower fluid weight gain in addition to lowered stress on the heart. Thus, technical advancements in WAK have the potential to reduce mortality in dialysis patients, which thereby improves an ESRD patient’s quality of life. The WAK prototypes designed and patented by innovative firms have been approved for human clinical trials by the U.S. FDA in 2016.

End Stage Renal Disease Market Report Highlights

• By treatment, the dialysis segment dominated the ESRD market in 2020 owing to its ease of use and emergency convenience

• The transplant treatment segment is expected to expand at the highest CAGR from 2021 to 2028

• Asia Pacific dominated the market in 2020 owing to the large population of patients with CKD/ESRD and greater incidence of hypertension and diabetes in the region

【レポートの目次】

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Treatment
1.1.2 Regional Scope
1.1.3 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information procurement
1.3.1 Purchased Database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.2 Volume Price Analysis (Model 2)
1.6.2.1 Approach 2: Volume price analysis
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 End Stage Renal Disease Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Product Pipeline Analysis
3.4 User Perspective Analysis
3.4.1 Consumer Behavior Analysis
3.4.2 Market Influencer Analysis
3.5 List of Key End Users
3.6 Regulatory Framework
3.7 Market Dynamics
3.7.1 Market Driver Analysis
3.7.1.1 Growing prevalence of diabetes and hypertension
3.7.1.2 Introduction of technologically advanced products
3.7.1.3 Increasing number of patients suffering from chronic kidney disease
3.7.2 Market Restraints Analysis
3.7.2.1 Risk of complications
3.7.2.2 Stringent regulatory policies for dialysis products
3.8 End Stage Renal Disease: Market Analysis Tools
3.8.1 Industry Analysis – Porter’s
3.8.2 Swot Analysis, By Pest
Chapter 4 End Stage Renal Disease Market: Segment Analysis, By Treatment, 2016 – 2028 (USD Million)
4.1 Definition and Scope
4.2 Treatment Market Share Analysis, 2020 & 2028
4.3 Segment Dashboard
4.4 Global End Stage Renal Disease Market, by Treatment, 2016 to 2028
4.5 Market Size & Forecasts and Trend Analysis, 2016 to 2028
4.5.1 Dialysis
4.5.1.1 Dialysis market, 2016 – 2028 (USD Million)
4.5.1.2 Peritoneal Dialysis
4.5.1.2.1 Peritoneal dialysis market, 2016 – 2028 (USD Million)
4.5.1.3 Hemodialysis
4.5.1.3.1 Hemodialysis market, 2016 – 2028 (USD Million)
4.5.1.4 Wearable Artificial Kidney
4.5.1.4.1 Wearable artificial kidney market, 2016 – 2028 (USD Million)
4.5.2 Transplant
4.5.2.1 Transplant market, 2016 – 2028 (USD Million)
Chapter 5 End Stage Renal Disease Market: Regional Market Analysis, By Treatment, 2016 – 2028 (USD Million)
5.1 Definition & Scope
5.2 Regional Market Share Analysis, 2020 & 2028
5.3 Regional Market Dashboard
5.4 Regional Market Snapshot
5.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
5.5.1 North America
5.5.2 Europe
5.5.3 Asia Pacific
5.5.4 Latin America
5.5.5 Middle East and Africa
5.6 Market Size, & Forecasts, Volume and Trend Analysis, 2016 to 2028
5.7 North America
5.7.1 North America End Stage Renal Disease Market, 2016 – 2028 (USD Million)
5.7.2 U.S.
5.7.2.1 U.S. end stage renal disease market, 2016 – 2028 (USD Million)
5.7.3 Canada
5.7.3.1 Canada end stage renal disease market, 2016 – 2028 (USD Million)
5.8 Europe
5.8.1 Europe End Stage Renal Disease Market, 2016 – 2028 (USD Million)
5.8.2 U.K.
5.8.2.1 U.K. end stage renal disease market, 2016 – 2028 (USD Million)
5.8.3 Germany
5.8.3.1 Germany end stage renal disease market, 2016 – 2028 (USD Million)
5.8.4 France
5.8.4.1 France end stage renal disease market, 2016 – 2028 (USD Million)
5.8.5 Italy
5.8.5.1 Italy end stage renal disease market, 2016 – 2028 (USD Million)
5.8.6 Spain
5.8.6.1 Spain end stage renal disease market, 2016 – 2028 (USD Million)
5.9 Asia Pacific
5.9.1 Asia Pacific end stage renal disease Market, 2016 – 2028 (USD Million)
5.9.2 Japan
5.9.2.1 Japan end stage renal disease market, 2016 – 2028 (USD Million)
5.9.3 China (Mainland)
5.9.3.1 China (Mainland) end stage renal disease market, 2016 – 2028 (USD Million)
5.9.4 India
5.9.4.1 India end stage renal disease market, 2016 – 2028 (USD Million)
5.9.5 Australia
5.9.5.1 Australia end stage renal disease market, 2016 – 2028 (USD Million)
5.9.6 South Korea
5.9.6.1 South Korea end stage renal disease market, 2016 – 2028 (USD Million)
5.10 Latin America
5.10.1 Latin America end stage renal disease Market, 2016 – 2028 (USD Million)
5.10.2 Brazil
5.10.2.1 Brazil end stage renal disease market, 2016 – 2028 (USD Million)
5.10.3 Mexico
5.10.3.1 Mexico end stage renal disease market, 2016 – 2028 (USD Million)
5.10.4 Argentina
5.10.4.1 Argentina end stage renal disease market, 2016 – 2028 (USD Million)
5.10.5 Colombia
5.10.5.1 Colombia end stage renal disease market, 2016 – 2028 (USD Million)
5.11 MEA
5.11.1 MEA end stage renal disease Market, 2016 – 2028 (USD Million)
5.11.2 South Africa
5.11.2.1 South Africa end stage renal disease market, 2016 – 2028 (USD Million)
5.11.3 Saudi Arabia
5.11.3.1 Saudi Arabia end stage renal disease market, 2016 – 2028 (USD Million)
5.11.4 UAE
6.11.4.1 UAE end stage renal disease market, 2016 – 2028 (USD Million)
Chapter 6 End Stage Renal Disease Market – Competitive Analysis
6.1 Recent Developments & Impact Analysis, by Key Market Participants
6.1.1 Nipro Corporation
6.2 Company Categorization
6.2.1 Innovators
6.2.2 Market Leaders
6.3 Vendor Landscape
6.3.1 Key Customers
6.3.2 Key Company Market Share Analysis, 2020
6.3.3 Major Deals And Strategic Alliances
6.3.3.1 New Product Launch
6.3.3.2 Expansion
6.3.3.3 Acquisition
6.3.3.4 Marketing & Promotions
6.3.4 Market Entry Strategies
6.4 Public Companies
6.4.1 Company Market Position Analysis
6.4.2 Competitive Dashboard Analysis
6.4.2.1 Market Differentiators
6.5 Private Companies
6.5.1 List of Key Emerging Companies
6.5.2 Regional Network Map
6.5.3 Company Market Position Analysis
6.6 Company Profiles
6.6.1 Medtronic
6.6.1.1 Company Overview
6.6.1.2 Financial Performance
6.6.1.3 Product Benchmarking
6.6.1.4 Strategic Initiatives
6.6.2 Fresenius Medical Care AG & Co. KGaA
6.6.2.1 Company Overview
6.6.2.2 Financial Performance
6.6.2.3 Product/Service Benchmarking
6.6.2.4 Strategic Initiatives
6.6.3 B. Braun Melsungen AG
6.6.3.1 Company Overview
6.6.3.2 Financial Performance
6.6.3.3 Product/Service Benchmarking
6.6.4 Baxter International, Inc.
6.6.4.1 Company Overview
6.6.4.2 Financial Performance
6.6.4.3 Product Benchmarking
6.6.4.4 Strategic Initiatives
6.6.5 Asahi Kasei Medical Co., Ltd.
6.6.5.1 Company Overview
6.6.5.2 Financial Performance
6.6.5.3 Product Benchmarking
6.6.5.4 Strategic Initiatives
6.6.6 Cantel Medical
6.6.6.1 Company Overview
6.6.6.2 Financial Performance
6.6.6.3 Product Benchmarking
6.6.6.4 Strategic Initiatives
6.6.7 BD
6.6.7.1 Company Overview
6.6.7.2 Financial Performance
7.6.7.3 Product Benchmarking
6.6.7.4 Strategic Initiatives
6.6.8 Nikkiso Co., Ltd.
6.6.8.1 Company Overview
6.6.8.2 Financial Performance
6.6.8.3 Product Benchmarking
6.6.8.4 Strategic Initiatives
6.6.9 JMS Co. Ltd.
6.6.9.1 Company Overview
6.6.9.2 Financial Performance
6.6.9.3 Product Benchmarking
6.6.9.4 Strategic Initiatives

List of Tables

Table 1. List of secondary sources
Table 2. List of abbreviation
Table 3. North America end stage renal disease market, by country, 2016 - 2028 (USD million)
Table 4. North America end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 5. U.S end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 6. Canada end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 7. Europe end stage renal disease market, by country, 2016 - 2028 (USD million)
Table 8. Europe end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 9. U.K. end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 10. Germany end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 11. France end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 12. Italy end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 13. Spain end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 14. Asia Pacific end stage renal disease market, by country, 2016 - 2028 (USD million)
Table 15. Asia Pacific end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 16. China end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 17. India end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 18. South Korea end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 19. Australia end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 20. Japan end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 21. Latin America end stage renal disease market, by country, 2016 - 2028 (USD million)
Table 22. Latin America end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 23. Brazil end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 24. Mexico end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 25. Argentina end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 26. Colombia end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 27. Middle East & Africa end stage renal disease market, by country, 2016 - 2028 (USD million)
Table 28. Middle East & Africa end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 29. South Africa end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 30. South Arabia end stage renal disease market, by treatment, 2016 - 2028 (USD million)
Table 31. UAE end stage renal disease market, by treatment, 2016 - 2028 (USD million)


List of Figures

Fig 1. End stage renal disease market segmentation
Fig 2. Market research process
Fig 3. Information procurement
Fig 4. Primary research pattern
Fig 5. Market research approaches
Fig 6. Value-chain-based sizing & forecasting
Fig 7. QFD modeling for market share assessment
Fig 8. Market formulation & validation
Fig 9. Market outlook (2020)
Fig 10. Segment Outlook
Fig 11. Strategy framework
Fig 12. Penetration & growth prospect mapping
Fig 13. Consumer behavior analysis
Fig 14. Market driver relevance analysis (Current & future impact)
Fig 15. Market restraint relevance analysis (Current & future impact)
Fig 16. Porter’s five forces analysis
Fig 17. SWOT analysis, by factor (political & legal, economic and technological)
Fig 18. End Stage Renal Disease market: Treatment movement analysis
Fig 19. Segment dashboard
Fig 20. End Stage Renal Disease market treatment outlook: Key takeaways
Fig 21. Dialysis market, 2016 - 2028 (USD Million)
Fig 22. Transplantation market, 2016 - 2028 (USD Million)
Fig 23. End Stage Renal Disease market: Regional movement analysis
Fig 24. Regional outlook, 2020 & 2028
Fig 25. Regional market dashboard
Fig 26. Regional market place: Key takeaways
Fig 27. North America, SWOT, by PEST
Fig 28. Europe, SWOT, by PEST
Fig 29. Asia Pacific, SWOT, by PEST
Fig 30. Latin America, SWOT, by PEST
Fig 31. Middle East and Africa, SWOT, by PEST
Fig 32. North America end stage renal disease market, 2016 - 2028 (USD Million)
Fig 33. U.S. end stage renal disease market, 2016 - 2028 (USD Million)
Fig 34. Canada end stage renal disease market, 2016 - 2028 (USD Million)
Fig 35. Europe end stage renal disease market, 2016 - 2028 (USD Million)
Fig 36. U.K. End Stage Renal Disease market, 2016 - 2028 (USD Million)
Fig 37. Germany end stage renal disease market, 2016 - 2028 (USD Million)
Fig 38. France end stage renal disease market, 2016 - 2028 (USD Million)
Fig 39. Italy end stage renal disease market, 2016 - 2028 (USD Million)
Fig 40. Spain end stage renal disease market, 2016 - 2028 (USD Million)
Fig 41. Asia Pacific end stage renal disease market, 2016 - 2028 (USD Million)
Fig 42. Japan end stage renal disease market, 2016 - 2028 (USD Million)
Fig 43. China (Mainland) end stage renal disease market, 2016 - 2028 (USD Million)
Fig 44. India end stage renal disease market, 2016 - 2028 (USD Million)
Fig 45. Australia end stage renal disease market, 2016 - 2028 (USD Million)
Fig 46. South Korea end stage renal disease market, 2016 - 2028 (USD Million)
Fig 47. Latin America end stage renal disease market, 2016 - 2028 (USD Million)
Fig 48. Brazil end stage renal disease market, 2016 - 2028 (USD Million)
Fig 49. Mexico end stage renal disease market, 2016 - 2028 (USD Million)
Fig 50. Argentina end stage renal disease market, 2016 - 2028 (USD Million)
Fig 51. Colombia end stage renal disease market, 2016 - 2028 (USD Million)
Fig 52. MEA end stage renal disease market, 2016 - 2028 (USD Million)
Fig 53. South Africa end stage renal disease market, 2016 - 2028 (USD Million)
Fig 54. Saudi Arabia end stage renal disease market, 2016 - 2028 (USD Million)
Fig 55. UAE end stage renal disease market, 2016 - 2028 (USD Million)
Fig 56. Nipro Corporation
Fig 57. Company market share analysis, by Dialysis
Fig 58. Company market share analysis, by Transplantation
Fig 59. Strategy mapping
Fig 60. Market differentiators
Fig 61. Regional network map

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の末期腎臓病市場2021-2028:治療別(移植、透析)、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆